Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
New Horizons for the Treatment of Cardiomyopathy in Children
NCT04893629 · Damascus University · NA · terminated · last registry update 2025-02-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of necessary equipment” | – | Registry record, Damascus University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-06Phase 3 first posted: Nanjing Sanhome Pharmaceutical, Co., Ltd., SH006 + Bevacizumab (NCT07392866)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-30Phase 3 first posted: Ningbo Newbay Technology Development Co., Ltd, NB003 + regorafenib (NCT07379047)
- 2026-01-29Results posted on the registry: Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-29Also stopped (terminated): Indiana University, Imatinib Mesylate (NCT03997903)
- 2026-01-20Results posted on the registry: Novartis Pharmaceuticals, Nilotinib (NCT00756509)
- 2026-01-20Results posted on the registry: Bristol-Myers Squibb, BMS-986288 + Nivolumab (NCT03994601)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
- 2026-01-09Results posted on the registry: M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2026-01-06Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Umbralisib (NCT04163718)
- 2025-12-23Phase 3 first posted: Xi'an Xintong Pharmaceutical Research Co.,Ltd., Pracytarabine + regorafenib (NCT07300488)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
- 2025-12-08Also stopped (terminated): M.D. Anderson Cancer Center, Ponatinib (NCT01570868)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-10-21Phase 3 first posted: GlaxoSmithKline, IDRX-42 + Sunitinib (NCT07218926)
- 2025-10-03Also stopped (terminated): National Cancer Institute (NCI), Dasatinib (NCT05198843)
- 2025-10-02Also stopped (terminated): Takeda, Ponatinib + Chemotherapy Agents (NCT04501614)
- 2025-10-02Phase 3 first posted: Nanfang Hospital, Southern Medical University, targeted drug (NCT07203352)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05064059)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
- 2025-09-10Results posted on the registry: Memorial Sloan Kettering Cancer Center, Regorafenib (NCT02098538)
- 2025-09-03Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, olverembatinib (NCT07152041)
- 2025-08-22Also stopped (terminated): OHSU Knight Cancer Institute, recombinant interferon alfa + imatinib mesylate (NCT00015847)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision